Comparative Pharmacology
Head-to-head clinical analysis: OVCON 50 versus PHILITH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OVCON 50 versus PHILITH.
OVCON-50 vs PHILITH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination estrogen-progestin contraceptive; suppresses gonadotropin release, inhibiting ovulation, and alters cervical mucus and endometrial lining.
PHILITH is a combined oral contraceptive containing ethinyl estradiol and drospirenone. Ethinyl estradiol suppresses gonadotropin release, while drospirenone is a progestin with antiandrogenic and antimineralocorticoid activity, inhibiting ovulation and altering cervical mucus.
One tablet (norethindrone 1 mg and ethinyl estradiol 50 mcg) orally once daily for 21 days followed by 7 days of placebo or no tablets.
1 mg orally once daily
None Documented
None Documented
Norethindrone: 5-14 hours (terminal); ethinyl estradiol: 7-20 hours. Clinical context: Steady-state reached within 5-7 days; half-life allows once-daily dosing with stable contraceptive efficacy.
Terminal half-life 12 hours; clinically relevant for twice-daily dosing with steady state reached after 2-3 days.
Renal: 40-60% (metabolites, primarily glucuronide conjugates; <1% unchanged). Fecal: 30-50% (via biliary elimination).
Renal: 90% unchanged; biliary/fecal: 10% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive